These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 29970109)

  • 1. Teriflunomide attenuates neuroinflammation-related neural damage in mice carrying human PLP1 mutations.
    Groh J; Hörner M; Martini R
    J Neuroinflammation; 2018 Jul; 15(1):194. PubMed ID: 29970109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting microglia attenuates neuroinflammation-related neural damage in mice carrying human PLP1 mutations.
    Groh J; Klein D; Berve K; West BL; Martini R
    Glia; 2019 Feb; 67(2):277-290. PubMed ID: 30565754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Teriflunomide for multiple sclerosis.
    He D; Zhang C; Zhao X; Zhang Y; Dai Q; Li Y; Chu L
    Cochrane Database Syst Rev; 2016 Mar; 3(3):CD009882. PubMed ID: 27003123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sialoadhesin promotes neuroinflammation-related disease progression in two mouse models of CLN disease.
    Groh J; Ribechini E; Stadler D; Schilling T; Lutz MB; Martini R
    Glia; 2016 May; 64(5):792-809. PubMed ID: 26775238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sex- and region-biased depletion of microglia/macrophages attenuates CLN1 disease in mice.
    Berve K; West BL; Martini R; Groh J
    J Neuroinflammation; 2020 Oct; 17(1):323. PubMed ID: 33115477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Teriflunomide and its mechanism of action in multiple sclerosis.
    Bar-Or A; Pachner A; Menguy-Vacheron F; Kaplan J; Wiendl H
    Drugs; 2014 Apr; 74(6):659-74. PubMed ID: 24740824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Teriflunomide Treatment of Multiple Sclerosis Selectively Modulates CD8 Memory T Cells.
    Tilly G; Cadoux M; Garcia A; Morille J; Wiertlewski S; Pecqueur C; Brouard S; Laplaud D; Degauque N
    Front Immunol; 2021; 12():730342. PubMed ID: 34721394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Teriflunomide for multiple sclerosis.
    He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
    Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Teriflunomide on B Cell Subsets in MuSK-Induced Experimental Autoimmune Myasthenia Gravis and Multiple Sclerosis.
    Yilmaz V; Ulusoy C; Hajtovic S; Turkoglu R; Kurtuncu M; Tzartos J; Lazaridis K; Tuzun E
    Immunol Invest; 2021 Aug; 50(6):671-684. PubMed ID: 32597289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual roles of the adenosine A2a receptor in autoimmune neuroinflammation.
    Ingwersen J; Wingerath B; Graf J; Lepka K; Hofrichter M; Schröter F; Wedekind F; Bauer A; Schrader J; Hartung HP; Prozorovski T; Aktas O
    J Neuroinflammation; 2016 Feb; 13():48. PubMed ID: 26920550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathogenic inflammation in the CNS of mice carrying human PLP1 mutations.
    Groh J; Friedman HC; Orel N; Ip CW; Fischer S; Spahn I; Schäffner E; Hörner M; Stadler D; Buttmann M; Varallyay C; Solymosi L; Sendtner M; Peterson AC; Martini R
    Hum Mol Genet; 2016 Nov; 25(21):4686-4702. PubMed ID: 28173160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world outcomes for a complete nationwide cohort of more than 3200 teriflunomide-treated multiple sclerosis patients in The Danish Multiple Sclerosis Registry.
    Papp V; Buron MD; Siersma V; Rasmussen PV; Illes Z; Kant M; Hilt C; Mezei Z; Roshanisefat H; Sejbæk T; Weglewski A; van Wingerden J; Geertsen SS; Bramow S; Sellebjerg F; Magyari M
    PLoS One; 2021; 16(5):e0250820. PubMed ID: 34003862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic dissection of oligodendroglial and neuronal Plp1 function in a novel mouse model of spastic paraplegia type 2.
    Lüders KA; Patzig J; Simons M; Nave KA; Werner HB
    Glia; 2017 Nov; 65(11):1762-1776. PubMed ID: 28836307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased Plp1 gene expression leads to massive microglial cell activation and inflammation throughout the brain.
    Tatar CL; Appikatla S; Bessert DA; Paintlia AS; Singh I; Skoff RP
    ASN Neuro; 2010 Sep; 2(4):e00043. PubMed ID: 20885931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatotoxicity associated with the use of teriflunomide in a patient with multiple sclerosis: A case report.
    Ferreira CM; Vasconcelos-Pereira EF; Oliveira VM; Salgado PR; Domingos JA; Monreal MTFD; Guerra-Shinohara EM; Gubert VT
    Medicine (Baltimore); 2021 Dec; 100(51):e28246. PubMed ID: 34941096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuronal injury in chronic CNS inflammation.
    Zindler E; Zipp F
    Best Pract Res Clin Anaesthesiol; 2010 Dec; 24(4):551-62. PubMed ID: 21619866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fingolimod and Teriflunomide Attenuate Neurodegeneration in Mouse Models of Neuronal Ceroid Lipofuscinosis.
    Groh J; Berve K; Martini R
    Mol Ther; 2017 Aug; 25(8):1889-1899. PubMed ID: 28506594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Teriflunomide Modulates Vascular Permeability and Microglial Activation after Experimental Traumatic Brain Injury.
    Prabhakara KS; Kota DJ; Jones GH; Srivastava AK; Cox CS; Olson SD
    Mol Ther; 2018 Sep; 26(9):2152-2162. PubMed ID: 30037655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Teriflunomide in Chinese Patients with Relapsing Forms of Multiple Sclerosis: A Subgroup Analysis of the Phase 3 TOWER Study.
    Qiu W; Huang DH; Hou SF; Zhang MN; Jin T; Dong HQ; Peng H; Zhang CD; Zhao G; Huang YN; Zhou D; Wu WP; Wang BJ; Li JM; Zhang XH; Cheng Y; Li HF; Li L; Lu CZ; Zhang X; Bu BT; Dong WL; Fan DS; Hu XQ; Xu XH;
    Chin Med J (Engl); 2018 Dec; 131(23):2776-2784. PubMed ID: 30511679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial.
    Chitnis T; Banwell B; Kappos L; Arnold DL; Gücüyener K; Deiva K; Skripchenko N; Cui LY; Saubadu S; Hu W; Benamor M; Le-Halpere A; Truffinet P; Tardieu M;
    Lancet Neurol; 2021 Dec; 20(12):1001-1011. PubMed ID: 34800398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.